ARTICLE | Company News
CHMP interactions delaying Coherus biosimilar timeline
June 25, 2018 10:56 PM UTC
Coherus Biosciences Inc. (NASDAQ:CHRS) lost $1.80 (10%) to $15.40 on Monday after it disclosed that EMA's CHMP will require further interactions with the company in order to issue an opinion on its pending MAA for CHS-1701, its biosimilar of Neulasta pegfilgrastim.
Coherus said it expects the interactions to occur prior to the next CHMP meeting, scheduled for July 23-26. The company said last month it was anticipating a CHMP opinion on or before June 28...
BCIQ Target Profiles